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Abstract 
Background: Arthritis pain is an important healthcare issue with significant emotional and affective consequences. 
Here we focus on potentially beneficial effects of activating small-conductance calcium-activated potassium (SK) 
channels in the amygdala, a brain center of emotions that plays an important role in central pain modulation and pro-
cessing. SK channels have been reported to regulate neuronal activity in the central amygdala (CeA, output nucleus). 
We tested the effects of riluzole, a clinically available drug for the treatment of amyotrophic lateral sclerosis, for the 
following reasons. Actions of riluzole include activation of SK channels. Evidence in the literature suggests that riluzole 
may have antinociceptive effects through an action in the brain but not the spinal cord. Mechanism and site of action 
of riluzole remain to be determined. Here we tested the hypothesis that riluzole inhibits pain behaviors by acting on 
SK channels in the CeA in an arthritis pain model.
Results: Systemic (intraperitoneal) application of riluzole (8 mg/kg) inhibited audible (nocifensive response) 
and ultrasonic (averse affective response) vocalizations of adult rats with arthritis (5 h postinduction of a kaolin-
carrageenan monoarthritis in the knee) but did not affect spinal withdrawal thresholds, which is consistent with a 
supraspinal action. Stereotaxic administration of riluzole into the CeA by microdialysis (1 mM, concentration in the 
microdialysis fiber, 15 min) also inhibited vocalizations, confirming the CeA as a site of action of riluzole. Stereotaxic 
administration of a selective SK channel blocker (apamin, 1 µM, concentration in the microdialysis fiber, 15 min) into 
the CeA had no effect by itself but inhibited the effect of systemic riluzole on vocalizations. Off-site administration of 
apamin into the basolateral amygdala (BLA) as a placement control or stereotaxic application of a selective blocker of 
large-conductance calcium-activated potassium (BK) channels (charybdotoxin, 1 µM, concentration in the microdialy-
sis fiber, 15 min) into the CeA did not affect the inhibitory effects of systemically applied riluzole.
Conclusions: The results suggest that riluzole can inhibit supraspinally organized pain behaviors in an arthritis model 
by activating SK, but not BK, channels in the amygdala (CeA but not BLA).
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Background
Pain is a multidimensional experience and includes signifi-
cant emotional-affective and cognitive components in addi-
tion to its sensory aspects, all of which can have a significant 
impact on patient quality of life [1–3]. The amygdala, a 
brain area for emotions, has been shown to play a key role 
in emotional-affective aspects of pain, emotion-driven cog-
nitive deficits and pain modulation in animal pain models 
and in human neuroimaging studies [3–6]. The amygdala 
neurocircuitry centered on pain processing includes the 
lateral-basolateral (LA-BLA) and central (CeA) nuclei [3, 4]. 
The LA-BLA complex receives polymodal sensory inputs 
from several brain regions and attaches affective informa-
tion, which is then relayed to the CeA. The CeA receives 
purely nociceptive information through the spino-parabra-
chio-amygdaloid tract and serves major output functions 
to generate emotional responses and modulate pain-related 
behavior. Activity of CeA neurons correlates positively with 
emotional responses and anxiety-like behaviors in different 
pain models [3, 4]. Therefore, normalizing CeA activity is a 
desirable strategy to inhibit pain.
Here we focus on potentially beneficial effects of acti-
vating small-conductance calcium-activated potassium 
(SK) channels in the amygdala. SK channels are widely 
expressed throughout the nervous system, including in 
the amygdala; they mediate the medium-type afterhy-
perpolarization (mAHP) and can regulate action poten-
tial firing, excitability, and synaptic transmission [7–9]. 
SK channels have been implicated in peripheral [10] and 
spinal [11, 12] antinociceptive processes, but their role in 
brain mechanisms of pain remain to be determined. We 
tested the effects of riluzole, a clinically available drug for 
the treatment of amyotrophic lateral sclerosis, because 
actions of riluzole include activation of SK channels [13] 
and some evidence in the literature suggests that riluzole 
may have antinociceptive effects through a supraspinal 
rather than spinal site of action. Systemically applied rilu-
zole had antinociceptive effects in the formalin test [14–
16], in the carrageenan model of hindpaw inflammation 
[17], and in neuropathic pain models of chronic constric-
tion injury [18], spinal root avulsion injury [19], cervical 
spondolytic myelopathy [20] and spinal cord compres-
sion [21]. In the latter study, intracerebroventricular but 
not intrathecal injection of riluzole was effective. Riluzole 
injected into the periaqueductal grey prevented nocic-
eptive behaviors induced by capsaicin injection into the 
periaqueductal grey [22]. Riluzole also had anxiolytic 
effects in the conditioned emotional response model of 
anxiety [16]. A clinical study found that riluzole produced 
pain relief in patients with irritable bowel syndrome [23].
Here we test the hypothesis that riluzole inhibits pain 
behaviors in an arthritis pain model, and that SK channels 
in the amygdala (CeA) contribute to this effect. It should be 
noted that there are a number of other targets of riluzole, 
including inhibition of voltage-gated sodium channels, 
inhibition of glutamatergic transmission, and increase of 
glutamate uptake [13, 24–27]. Inhibition of glutamatergic 
signaling has been suggested as a potential mechanism of 
riluzole’s antinociceptive effects, but riluzole has not been 
directly linked to proposed interactions with NMDA recep-
tors [26] or glutamate transporters [25]. Furthermore, 
behavioral effects of riluzole can be similar to those of com-
petitive NMDA receptor antagonists, but NMDA receptor 
activation did not reverse riluzole effects [28]. Therefore, 
effects of riluzole on glutamatergic transmission could be 
indirect and possibly linked to its action on SK channels. In 
fact, SK channels have been shown to interact functionally 
with NMDA receptors and shunt excitatory transmission 
in the spinal cord, amygdala, and prefrontal cortex [12, 29, 
30]. The contribution of SK channels to any pain inhibiting 
effects of riluzole remains to be determined.
Key novelties of this study are the site of action of 
riluzole in the brain, involvement of SK channels in the 
effects of riluzole, and pain inhibiting effects of SK chan-
nel activation in the brain (amygdala).
Results
Systemically applied riluzole inhibits vocalizations
Vocalizations in the audible (20  Hz–16  kHz) and ultra-
sonic (25  ±  4  kHz) ranges, corresponding to supraspi-
nally organized nocifensive and averse affective 
responses, respectively, were evoked by brief (15 s) nox-
ious (1000–1500  g/30  mm2) mechanical stimulation of 
the knee joint with a calibrated forceps as described pre-
viously [31–33]. Duration of vocalizations was measured 
for a period of 1 min, starting with the onset of the stim-
ulus, in normal naïve rats and in another group of rats 
before and 5  h postinduction of a kaolin/carrageenan-
induced knee joint arthritis (see “Methods”).
In normal naïve rats, systemic injection of riluzole (8 mg/
kg, i.p.; n =  6 rats) decreased the duration of ultrasonic 
(Fig. 1b) but not audible (Fig. 1a) vocalizations evoked by 
noxious stimulation of the knee joint compared to vehicle 
(2-hydroxypropyl-β-cyclodextrin, HBC, 30  %, i.p.) tested 
in the same rats (P  <  0.05, paired t test). Induction of 
arthritis resulted in a significant increase in the duration of 
audible (Fig. 1c) and ultrasonic (Fig. 1d) vocalizations com-
pared to normal (P  <  0.001, repeated measures one-way 
ANOVA with Bonferroni posttests). Systemic application 
of riluzole (8 mg/kg, i.p.; n = 19 rats) decreased the vocali-
zations of arthritic rats compared to predrug and vehicle 
(HBC, 30 %, i.p.; n = 16 rats) significantly (P < 0.05–0.001, 
repeated measures one-way ANOVA and unpaired t test 
with Bonferroni correction/posttests).
The dose of 8  mg/kg was chosen because a previous 
study showed that this was the lowest dose that produced 
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antinociceptive effects in a spinal cord injury model [21]. 
Vocalizations were measured 60  min postinjection of 
riluzole because preliminary data indicated a maximum 
effect of riluzole at this time point when tested every 
30 min for 3 h. In a subset of rats (n = 6) that were tested 
1 h and 2.5 h after systemic application of riluzole (8 mg/
kg, i.p.), we found that the inhibitory effects of riluzole 
on audible and ultrasonic vocalizations had disappeared 
2.5 h post-injection compared to vehicle control values.
Riluzole has no effect on hindlimb withdrawal responses
Hindlimb withdrawal thresholds were measured by com-
pressing the knee joint with gradually increasing force 
using a calibrated forceps whose output was displayed on 
an LCD screen until a withdrawal response was observed 
as described in our previous studies [31, 33] (see “Meth-
ods”). Reflex thresholds were significantly decreased 5 h 
postinduction of arthritis (P < 0.001, repeated measures 
one-way ANOVA with Bonferroni posttests; Fig. 2). Sys-
temic application of riluzole (8 mg/kg, i.p.; n = 7 rats) or 
vehicle (HBC, 30 %, i.p.; n = 11) had no effect compared 
to predrug control values (P  >  0.05; repeated measures 
one-way ANOVA with Bonferroni posttests; Fig. 2).
Riluzole inhibits vocalizations through an action on SK 
channels in the CeA but not BLA
To determine site of action in the brain, we injected rilu-
zole (1  mM, concentration in the microdialysis fiber, 
15  min) stereotaxically into the central nucleus of the 
amygdala (CeA) by microdialysis and measured its effect 
on vocalizations of arthritic rats (5  h postinduction). 
Microdialysis has been used routinely in our previous 
studies for drug application into different brain areas (for 
recent publications see [32–34]). Riluzole administered 
into the CeA significantly decreased the duration of audi-
ble (Fig. 3a) and ultrasonic (Fig. 3b) vocalizations evoked 
by noxious stimulation of the knee compared to predrug 
values (n = 8 rats; P < 0.05–0.01; paired t test). Position 
of microdialysis probes in the CeA was verified histologi-
cally (Fig. 4a).
To assess the contribution of SK channels in the CeA 
to the inhibitory effects of riluzole, a selective SK chan-
nel blocker (apamin, 1 μM, concentration in the micro-
dialysis fiber, 15  min) was stereotaxically applied into 
the CeA of arthritic rats (5  h postinduction), starting 
45  min after systemic injection of riluzole (8  mg/kg, 
i.p.). Vocalizations were measured 15  min later, i.e., at 
Fig. 1 Inhibitory effects of systemically applied riluzole on 
vocalizations. a, b Riluzole (8 mg/kg, i.p.) had no effect on audible 
vocalizations (a) but inhibited ultrasonic vocalizations (b) to noxious 
stimulation of the knee joint compared to vehicle in normal naïve rats 
(n = 6). n.s. non-significant; *P < 0.05; paired t test. c, d Induction of 
arthritis resulted in a significant increase of audible (c) and ultrasonic 
(d) vocalizations evoked by noxious stimuli. Riluzole (8 mg/kg, i.p.; 
n = 19 rats) inhibited vocalizations of arthritic rats compared to 
predrug and vehicle (HBC, 30 %, i.p.; n = 16 rats). n.s. non-significant; 
*,**,***P < 0.05, 0.01, 0.001; repeated measures one-way ANOVA (com-
pared to predrug) and unpaired t test (compared to vehicle) with 
Bonferroni posttests/correction. Bar histograms show mean ± SEM
Fig. 2 Lack of effect of systemically applied riluzole on spinal 
withdrawal thresholds. Induction of arthritis significantly reduced 
hindlimb withdrawal thresholds measured by mechanical compres-
sion of the knee joint. Systemic application of vehicle (HBC, 30 %, 
i.p.; n = 11 rats) or riluzole (8 mg/kg, i.p.; n = 7 rats) had no effect 
compared to predrug values. Bar histograms show mean ± SEM. n.s. 
non-significant; ***P < 0.001; repeated measures one-way ANOVA 
with Bonferroni posttests
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1 h post-injection of riluzole. In the presence of apamin 
in the CeA, systemically applied riluzole had no effect 
on audible (Fig.  5a) or ultrasonic (Fig.  5b) vocalizations 
compared to predrug control values (n = 9 rats; P > 0.05; 
paired t test). In contrast, stereotaxic administration 
of artificial cerebrospinal fluid (ACSF, 15  min) into the 
CeA as a control did not block the effect of systemically 
applied riluzole, and so riluzole was able to inhibit audi-
ble (Fig.  5a) and ultrasonic (Fig.  5b) vocalizations com-
pared to predrug control values (n  =  9 rats; P  <  0.01; 
paired t test). Position of microdialysis probes in the CeA 
was verified histologically (Fig. 4b).
To determine if the involvement of SK channels was 
specific to the CeA, placement control experiments 
were performed in arthritic rats (5 h postinduction) and 
apamin (1 μM, concentration in the microdialysis probe, 
15  min) was administered stereotaxically into the BLA, 
which is a major source of input to the CeA [3]. Apamin 
administration started 45  min after systemic application 
of riluzole (8 mg/kg, i.p.) and vocalizations were measured 
15 min later, i.e., at 1 h post-injection of riluzole. Apamin 
administered into the BLA did not block the significant 
inhibitory effects of riluzole (n =  6 rats; P  <  0.05, com-
pared to predrug, paired t test) on audible (Fig.  5c) and 
ultrasonic (Fig. 5d) vocalizations. Position of microdialy-
sis probes in the BLA was verified histologically (Fig. 4b).
BK channels in the CeA are not involved in the effects 
of riluzole
To assess a contribution of large-conductance calcium-
activated potassium (BK) channels to the inhibitory 
effects of riluzole, a selective BK channel blocker (cha-
rybdotoxin, 1  μM, concentration in the microdialysis 
probe, 15 min) was administered stereotaxically into the 
CeA of arthritic rats (n = 5 rats; 5 h postinduction), start-
ing 45 min after systemic injection of riluzole (8 mg/kg, 
i.p.). Vocalizations were measured 15 min later, i.e., at 1 h 
post-injection of riluzole. Charybdotoxin did not affect 
the effects of systemically applied riluzole and so riluzole 
inhibited audible (Fig. 5c) and ultrasonic (Fig. 5d) vocali-
zations significantly compared to predrug control values 
(P < 0.05; paired t test). Position of microdialysis probes 
in the CeA was verified histologically (Fig. 4c).
SK channel blockade in the CeA has no effect 
on vocalizations and hindlimb withdrawal responses
The data so far show an important contribution of SK, 
but not BK, channels in the CeA, but not BLA, to the 
inhibitory effects of riluzole. To assess the role of SK 
channels in pain-related behaviors, we measured the 
effect of apamin (1 μM, concentration in the microdialy-
sis probe, 15  min) administered stereotaxically into the 
CeA on vocalizations of arthritic rats (n  =  7). Apamin 
by itself had no significant effect on audible (Fig. 6a) or 
ultrasonic (Fig.  6b) vocalizations, or on hindlimb with-
drawal thresholds (data not shown), compared to pre-
drug control values (P  >  0.05; paired t test), but there 
was a trend because some rats showed increased vocali-
zations during apamin application (audible, three rats; 
ultrasonic, four rats; see gray symbols in Fig. 4b). Position 
of microdialysis probes in the CeA was verified histologi-
cally (Fig. 4b).
Discussion
Key findings of this study are that riluzole is antinocicep-
tive in an arthritis pain model and that this effect involves 
activation of small-conductance calcium-activated potas-
sium (SK) channels, but not large-conductance calcium-
activated potassium (BK) channels, in the central nucleus 
of the amygdala (CeA). To the best of our knowledge, 
this is the first study to show that SK channel activation 
in the amygdala can inhibit pain-related behaviors. These 
findings are significant because they demonstrate pre-
clinical efficacy of a clinically-available drug (riluzole) for 
the treatment of pain, provide information about mecha-
nisms and site of action, and suggest that SK channels in 
the amygdala could be targeted for pain management.
Riluzole is a clinically available compound approved 
by the US Food and Drug Administration (FDA) for the 
treatment of amyotrophic lateral sclerosis (ALS). Rilu-
zole is currently in clinical trials for a phase 2/3 study 
on spinal cord injury treatment (“Riluzole in Spinal 
Cord Injury Study”, RISCIS; clinicaltrials.gov Identifier: 
NCT01597518), a phase 1/2 study on post-traumatic 
stress disorder [“Safety Study of Riluzole to Treat Post-
traumatic Stress Disorder (PTSD)”; ClinicalTrials.
Fig. 3 Inhibitory effects of riluzole administered into the amygdala 
(CeA) in arthritic rats. Stereotaxic administration of riluzole (1 mM, 
concentration in the microdialysis probe, 15 min) into the CeA of 
arthritic rats (n = 8 rats; 5 h postinduction) significantly inhibited 
audible (a) and ultrasonic (b) vocalizations evoked by noxious stimu-
lation of the knee joint compared to predrug values. Bar histograms 
show mean ± SEM. *,**P < 0.05, 0.01; paired t test
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Fig. 4 Location of microdialysis probes for stereotaxic drug application. Symbols show the positions of the tips of microdialysis probes for drug 
application into amygdala regions. CeA, filled circles; BLA, open circles. a Positions of microdialysis probes for stereotaxic application of riluzole into 
the CeA. b Positions of microdialysis probes for stereotaxic application of apamin into CeA or BLA; gray symbols indicate sites of apamin injection 
that increased vocalizations. c Positions of microdialysis probes for stereotaxic application of charybdotoxin (ChTx) into CeA or BLA. Diagrams show 
coronal brain slices. Numbers indicate distance from the bregma
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gov Identifier: NCT02155829], and a phase 2 study for 
depression (“efficacy and tolerability of riluzole in treat-
ment resistant depression”; ClinicalTrials.gov Identifier: 
NCT01204918). Riluzole has been investigated in pre-
clinical and clinical studies for beneficial effects in pain. 
Riluzole had antinociceptive effects in rodent models of 
inflammatory [14, 16, 17] and neuropathic pain [18–21] 
and produced pain relief in patients with irritable bowel 
syndrome [23] and a slight pain reduction in patients 
with peripheral neuropathic pain, though no overall 
significant effect compared to placebo [35]. A study in 
healthy volunteers reported a reduction of median pain 
during thermal injury on the distal leg at the time point 
when maximum plasma concentrations of riluzole were 
expected (90 min after oral application), but riluzole had 
no analgesic effects in normal skin or on mechanical 
and thermal cutaneous hypersensitivity hours after burn 
injury [36].
Some preclinical evidence pointed to a supraspinal 
site of action of riluzole. Intracerebroventricular, but 
not intrathecal, injection of riluzole was effective in neu-
ropathic spinal cord injury pain [21], although another 
study found that systemically applied riluzole inhibited 
spinal glutamate release in the formalin pain model [15]. 
Antinociceptive effects of riluzole in a carrageenan-
induced inflammatory pain model were accompanied 
by decreased concentrations of glutamate and aspartate 
in the thalamus [17]. Riluzole injected into the periaq-
ueductal grey prevented capsaicin-induced nociceptive 
behaviors [22]. The site of antinociceptive action of rilu-
zole is not clear yet. Here we identified the amygdala 
(CeA) and SK channels as a site and mechanism of action 
of riluzole in an arthritis pain model. Systemic adminis-
tration of riluzole resulted in a significant attenuation of 
supraspinally organized vocalizations but not hindlimb 
withdrawal responses. Lack of effects on withdrawal 
thresholds argues against motor deficits and non-specific 
generalized effects such as a local anesthetic action from 
sodium channel blockade.
The results of the present study identify the amygdala as 
a site of action because stereotaxic application of riluzole 
into the CeA inhibited pain behaviors and intra-CeA appli-
cation of an SK channel blocker (apamin) prevented the 
antinociceptive effects of systemic riluzole. These effects 
were specific for SK channels in the CeA because they 
Fig. 5 Involvement of SK, but not BK, channels in the CeA, but not 
BLA, in the inhibitory effects of riluzole in arthritis. a, b Systemic 
riluzole (8 mg/kg, i.p.) had no effect on audible (a) and ultrasonic 
(b) vocalizations compared to predrug values, when an SK channel 
blocker (apamin, 1 μM, concentration in the microdialysis probe, 
15 min) was administered stereotaxically into the CeA of arthritic rats 
(n = 9 rats; 5 h postinduction). When ACSF was administered into the 
CeA, systemic riluzole inhibited vocalizations of arthritic rats signifi-
cantly compared to predrug values (n = 9 rats). n.s. non-significant; 
**P < 0.01; paired t test. c, d Stereotaxic application of a BK channel 
blocker (charybdotoxin, ChTx, 1 μM, concentration in the microdialy-
sis probe, 15 min) into the CeA (n = 5 rats) or stereotaxic application 
of apamin (1 μM, concentration in the microdialysis probe, 15 min) 
into the BLA (n = 6 rats) did not block the significant inhibitory 
effects of systemic riluzole on audible (c) and ultrasonic (d) vocaliza-
tions of arthritic rats compared to predrug values. n.s. non-significant; 
*,**P < 0.05; paired t test. Bar histograms show mean ± SEM
Fig. 6 Lack of effect of SK channel blockade alone on vocalizations in 
arthritic rats. Stereotaxic application of a selective SK channel blocker 
(apamin, 1 μM, concentration in the microdialysis probe, 15 min) into 
the CeA alone had no significant effect on audible (a) and ultra-
sonic (b) vocalizations of arthritic rats (n = 7 rats; 5 h postinduction) 
compared to predrug values. Bar histograms show mean ± SEM. n.s. 
non-significant; paired t test
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were not mimicked by apamin application into another 
amygdala area (BLA) or by application of a BK channel 
blocker (charybdotoxin) into the CeA, and so these find-
ings further argue against non-specific actions. It should 
be noted that functional SK channels contributing to the 
medium AHP have been reported in the lateral amygdala 
area, but they do not regulate action potential firing fre-
quency [37]. Therefore, it is possible that apamin-induced 
block of SK channels in the lateral-basolateral area of the 
amygdala did not translate into a significant effect on 
amygdala output from the CeA because SK channels do 
not regulate BLA neuronal firing. It should be noted that 
the present study does not rule out contributions of other 
brain regions or other molecular targets to the antinocic-
eptive effects of riluzole. SK channel blockade in the CeA 
by itself (without riluzole), had no significant behavioral 
effects in the pain model, perhaps suggesting that SK chan-
nels are not endogenously activated or are not sufficient to 
control amygdala-dependent behaviors. Furthermore, this 
finding suggests that the reversal of inhibitory effects of 
systemic riluzole by intra-CeA apamin was not due to an 
indirect effect but instead a specific blockade of riluzole 
actions. There was a trend for apamin to increase vocaliza-
tions in about half of the sample of rats and so there could 
be inter-individual variability involving SK channels. Com-
parison of the injection sites that increased vocalizations 
and those that had no effect did not show evidence for site 
specific actions within the CeA.
While this study was motivated in part by the clini-
cal availability of a compound (riluzole) that acts on SK 
channels, inhibition of glutamate signaling could also 
mediate the antinociceptive effects [24–26], although this 
may be an indirect effect of riluzole and could be the con-
sequence of SK channel activation such as shunting excit-
atory transmission [37]. SK channels have been shown to 
modulate NMDA receptor mediated currents, indicating 
that SK channel activation could be responsible for the 
indirect inhibition of glutamate function observed with 
riluzole [30, 38]. Activation of SK channels in the spinal 
cord had antinociceptive effects and reduced the dose of 
an NMDA receptor blocker needed to attenuate mechan-
ical hypersensitivity in an inflammatory pain model [12]. 
Data from the present study suggest that amygdala-
mediated actions of riluzole on pain-related behaviors 
depend on SK channels. Pain-related consequences and 
downstream effects of SK channel activation remain to 
be determined.
Our studies rely on the choice of appropriate concen-
trations for systemic and focal (by microdialysis) applica-
tion. The dose of systemically applied riluzole (8 mg/kg) 
has been shown to have antinociceptive effects in previ-
ous studies [15, 20, 21]. For stereotaxic drug application 
by microdialysis, a concentration 100-fold greater than 
that needed in the tissue was selected based on published 
data (riluzole, [13]; apamin, [37]; charybdotoxin, [39]). 
Our previous studies comparing drug effects in brain 
slices with drug application by microdialysis in intact ani-
mals determined that microdialysis required a 100-fold 
higher concentration because of the concentration gradi-
ent across the dialysis membrane and diffusion in the tis-
sue [32, 40–43]. Riluzole, being a small molecule, might 
be expected to have a higher transfer efficiency across the 
microdialysis membrane than the comparatively larger 
peptides apamin and charybdotoxin. However, previ-
ous studies with stereotaxic application of similar small 
molecules and peptides have indicated that the 100-fold 
concentration gradient is appropriate for transfer in both 
situations [32, 41, 43]. However, we cannot rule com-
pletely that reduced transfer efficiency contributed to the 
inability of charybdotoxin to block the inhibitory effects 
of systemic riluzole.
A number of other questions arise from the results 
of this behavioral study that warrant further research. 
While our data implicate SK channels in the inhibitory 
effects of riluzole, the role of SK channels in the amyg-
dala in pain remains to be determined. Behavioral and 
electrophysiological effects of selective SK channel acti-
vators and synaptic and cellular mechanisms and site(s) 
of action of SK channels should be investigated. Here we 
focused on the effects of riluzole because it is a clinically 
available compound. Detailed electrophysiological analy-
sis of its actions in the amygdala circuitry is needed. And 
while the present study focused on emotional responses 
in a relatively acute pain model (knee joint arthritis), it 
would be important to measure effectiveness of riluzole 
in more chronic models and on other parameters such as 
anxiety and depression.
Conclusions
SK channel activation in the amygdala (CeA) plays an 
important role in the antinociceptive effects of riluzole 
in an arthritis pain model, suggesting that SK channels 
in that brain area may be useful targets for pain relief 
and are accessible to systemically administered clinically 
available compounds. To the best of our knowledge this 
is the first study to link SK channels in the amygdala to 
pain modulation.
Methods
Adult male Sprague–Dawley rats (180–350  g) were 
housed in a temperature-controlled room and main-
tained on a 12-h  day/night cycle with unrestricted 
access to food and water. Experimental procedures were 
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at Texas Tech University Health Sci-
ences Center.
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Experimental protocol
Pain behaviors were measured before and 5  h after 
induction of a mono-arthritis in the left knee joint. 
To test the effects of systemic (intraperitoneal, i.p.) 
application of riluzole, pain behaviors (see “Pain-
related behaviors”) were measured 1  h postinjection 
in normal and arthritic animals. To determine effects 
of drug application into the amygdala, pain behaviors 
were measured 15  min after starting drug applica-
tion through a stereotaxically implanted microdialysis 
probe. To investigate site of action in the amygdala of 
systemically applied riluzole, potassium channel block-
ers (or ACSF) were administered into the amygdala 
45  min after systemic application of riluzole and pain 
behaviors were measured 15 min later, i.e., 1 h postin-
jection of riluzole (i.p.).
Arthritis pain model
Rats were briefly anesthetized with isoflurane (2–3  %) 
and a mono-arthritis was induced by injections of kaolin 
(4 %, 100 μl) and carrageenan (2 %, 100 μl) into the left 
knee joint cavity through the patellar ligament followed 
by repetitive flexion and extension of the leg for several 
minutes after each injection [31]. Testing began 5 h post-
injections because electrophysiological and behavioral 
changes reach a plateau at this time point [31].
Stereotaxic drug application into the amygdala 
by microdialysis
These procedures have been described in our previous 
studies (for recent publications see [32, 33, 44]). On Day 
1, a guide cannula was inserted into the right CeA. Rats 
were anesthetized with isoflurane (2–3  %) and placed 
in a stereotaxic frame (David Kopf Instruments). After 
a unilateral craniotomy, a guide cannula (CMA/Micro-
dialysis, Solna, Sweden) was stereotaxically inserted 
into the right CeA using the following coordinates [45]: 
2.1 mm caudal to bregma, 4 mm lateral to midline, and 
7 mm deep. The cannula was fixed to the skull with den-
tal acrylic (Plastic One, Roanoke, VA, USA). Bacitracin 
ointment was applied to the exposed tissue to prevent 
infection. For offsite control injections, cannulas were 
implanted lateral to the CeA into the BLA (see Fig. 4b). 
On Day 2, a microdialysis probe (CMA/Microdialysis 
11, Solna, Sweden) extending 1 mm beyond the cannula 
was inserted and connected to an infusion pump (Har-
vard Apparatus, Holliston, MA, USA) using polyethyl-
ene tubing. Drug (riluzole, apamin, or ChTx) or vehicle 
(ACSF) was applied for 15  min at a rate of 5  μl/min 
before behavioral testing to establish tissue equilibrium. 
Location of the tips of the microdialysis probes were 




Vocalizations in the audible (20  Hz–16  kHz) and ultra-
sonic (25 ±  4  kHz) ranges were measured using a con-
denser microphone connected to a preamplifier, and 
bat detector connected to a filter and amplifier (Ultra-
Vox 4-channel system; Noldus Information Technol-
ogy), respectively, as described previously [31, 46]. Rats 
were briefly anesthetized with isoflurane and positioned 
comfortably in a custom-designed recording chamber 
(US Patent 7,213,538) at a fixed distance from the sound 
detectors. Brief (15  s) innocuous (100–500  g/30  mm2) 
and noxious (1000–1500 g/30 mm2) stimuli were applied 
to the knee with a calibrated forceps equipped with a 
force transducer whose output signal was amplified and 
displayed in grams on an LED screen. Vocalizations were 
recorded for 1 min starting with the onset of the mechan-
ical stimulus and analyzed using Ultravox 2.0 software 
(Noldus Information Technology).
Hindlimb withdrawal responses
Withdrawal thresholds were determined after the 
vocalization assay as described previously [31]. A cali-
brated forceps with force transducer was used to apply a 
mechanical stimulus of continuously increasing intensity 
to the left knee joint until a withdrawal reflex was evoked. 
Withdrawal threshold was defined as the force required 
for a reflex response.
Histological verification of injection sites
The position of the microdialysis probe was confirmed 
histologically. Animals were euthanized by decapitation 
using a guillotine (Harvard Apparatus Decapitator) at the 
end of the experiment, and brains were removed rapidly 
and submerged in 4 % paraformaldehyde at 4 °C for 24 h. 
Tissues were stored in 30 % sucrose and frozen sectioned 
at 50  μm. Sections were mounted on gel-coated glass 
slides and stained with hematoxylin and eosin (H&E) 
before cover slipping. Sections were analyzed under the 
microscope and positions of the tip of the probes were 
identified and plotted on diagrams adapted from [45].
Drugs
The following drugs were used: riluzole [2-amino-6-
(trifluoromethoxy)benzothiazole] was purchased from 
Sigma-Aldrich and dissolved in 2-hydroxypropyl-β-
cyclodextrin (HBC, Sigma-Aldrich; 30  %), which served 
as the vehicle control for systemic drug injection. Total 
volume was increased to 1 ml with 0.9 % isotonic saline 
for i.p. injections (containing <10  % HBC). For stere-
otaxic administration by microdialysis, riluzole was 
diluted in ACSF from a stock solution made with HBC 
(30 %). Apamin (SK channel blocker) and charybdotoxin 
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(BK channel blocker) were purchased from Tocris Bio-
science (R&D Systems, Minneapolis, MN, USA). For 
stereotaxic administration by microdialysis, apamin and 
charybdotoxin were dissolved ACSF, which served as a 
vehicle control.
Statistics
Statistical significance was accepted at the level P < 0.05. 
All averaged values are presented as means  ±  SEM. 
GraphPad Prism 3.0 software (Graph-Pad Software, San 
Diego, CA, USA) was used for analysis. Repeated meas-
ures one-way ANOVA with Bonferroni posttests and 
paired t tests were used where appropriate.
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